391 results on '"Theodorakakou, Foteini"'
Search Results
2. Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity
3. Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece
4. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy
5. Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes
6. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study
7. Transthyretin amyloidosis cardiomyopathy in Greece: Clinical insights from the National Referral Center
8. ciRS‐7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma
9. Longitudinal Changes of Cardiac Magnetic Resonance Parameters in Response to Treatment for Cardiac Light-Chain Amyloidosis
10. Small Fiber Neuropathy in AL Amyloidosis: Clinical and Prognostic Implications
11. Long-term hematologic remission in Immunoglobulin Light Chain (AL) Amyloidosis
12. Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network
13. Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network
14. Predictive value of free light chain burden in patients newly diagnosed with AL amyloidosis treated with CyBorD or DaraCyBorD
15. Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative study
16. The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis
17. Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies
18. Monoclonal antibody-based therapies for Waldenström's macroglobulinemia
19. Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
20. Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study
21. Thrombotic and bleeding complications in patients with AL amyloidosis
22. Single‐cell analysis of MYD88L265P and MYD88WT Waldenström macroglobulinemia patients
23. Belantamab mafodotin, lenalidomide, and dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin‐associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study
24. CMR in AL Amyloidosis and Sarcoidosis. Do Look for Splenic Involvement
25. Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosis.
26. Left Ventricular Myocardial Work Improves in Response to Treatment and is Associated with Survival Among Patients with Light-Chain Cardiac Amyloidosis
27. Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies
28. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
29. Single‐cell analysis of MYD88L265P and MYD88WT Waldenström macroglobulinemia patients.
30. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
31. P-301 Real-world outcomes of belantamab mafodotin monotherapy in triple class refractory patients with multiple myeloma
32. P-122 Ocular adverse events and functional impact in transplant ineligible, newly diagnosed multiple myeloma patients treated with belantamab mafodotin, lenalidomide and dexamethasone in BelaRd trial
33. P-426 Thrombotic and bleeding complications in patients with AL amyloidosis
34. P-477 Pre-exposure prophylaxis for COVID-19 with tixagevimab/cilgavimab (evusheld) in patients with multiple myeloma in the omicron SARS-COV-2 era
35. OA-14 Persistent bone marrow and imaging MRD negativity may guide the duration of lenalidomide maintenance following ASCT in patients with multiple myeloma
36. P-123 Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: the phase 1/2 BelaRd study
37. P-117 A prognostic score based on age, eGFR (CKD-EPI), performance status and ultra-high-risk disease outperforms R2-ISS for elderly myeloma patients: an analysis of the Greek myeloma study group registry
38. Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation
39. Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab‐based therapy
40. P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY
41. P826: THE CIRCULAR RNA OF THE CHAPERONIN-CONTAINING TCP1 SUBUNIT 3 GENE (CIRC-CCT3) IS OVEREXPRESSED IN MULTIPLE MYELOMA AND PREDICTS A FAVORABLE PROGNOSTIC OUTCOME, INDEPENDENTLY OF THE R-ISS STAGING
42. S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
43. PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
44. PB2124: EFFICACY AND IMMUNE MODULATION OF DARATUMUMAB PLUS IMID COMBINATION IN PATIENTS REFRACTORY TO BOTH AGENTS“
45. P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
46. P884: BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY
47. P914: VENETOCLAX IN RELAPSE/REFRACTORY AL AMYLOIDOSIS- A MULTICENTER INTERNATIONAL RETROSPECTIVE REAL-WORLD STUDY
48. P834: MULTIPARAMETRIC FLOW CYTOMETRY FOR THE DETECTION OF CIRCULATING TUMOR CELLS IN PATIENTS WITH IGM MONOCLONAL GAMMOPATHIES
49. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
50. Kiosk 8R-TA-10 - CMR in AL Amyloidosis and Sarcoidosis. Do Look for Splenic Involvement
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.